PMID- 32794385
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20240219
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 45
IP  - 5
DP  - 2021 Sep
TI  - Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in 
      Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, 
      Observational Study.
PG  - 675-683
LID - 10.4093/dmj.2020.0107 [doi]
AB  - BACKGROUND: Only few studies have shown the efficacy and safety of 
      glucose-control strategies using the quadruple drug combination. Therefore, the 
      aim of the present study was to investigate the usefulness of the quadruple 
      combination therapy with oral hypoglycemic agents (OHAs) in patients with 
      uncontrolled type 2 diabetes mellitus (T2DM). METHODS: From March 2014 to 
      December 2018, data of patients with T2DM, who were treated with quadruple 
      hypoglycemic medications for over 12 months in 11 hospitals in South Korea, were 
      reviewed retrospectively. We compared glycosylated hemoglobin (HbA1c) levels 
      before and 12 months after quadruple treatment with OHAs. The safety, maintenance 
      rate, and therapeutic patterns after failure of the quadruple therapy were also 
      evaluated. RESULTS: In total, 357 patients were enrolled for quadruple OHA 
      therapy, and the baseline HbA1c level was 9.0%+/-1.3% (74.9+/-14.1 mmol/mol). After 
      12 months, 270 patients (75.6%) adhered to the quadruple therapy and HbA1c was 
      significantly reduced from 8.9%+/-1.2% to 7.8%+/-1.3% (mean change, -1.1%+/-1.2%; 
      P<0.001). The number of patients with HbA1c <7% increased significantly from 5 to 
      68 (P<0.005). In addition, lipid profiles and liver enzyme levels were also 
      improved whereas no changes in body weight. There was no significant safety issue 
      in patients treated with quadruple OHA therapy. CONCLUSION: This study shows the 
      therapeutic efficacy of the quadruple OHA regimen T2DM and demonstrates that it 
      can be an option for the management of T2DM patients who cannot use insulin or 
      reject injectable therapy.
FAU - Moon, Jun Sung
AU  - Moon JS
AD  - Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, 
      Korea.
FAU - Suh, Sunghwan
AU  - Suh S
AD  - Department of Internal Medicine, Dong-A University Medical Center, Dong-A 
      University College of Medicine, Busan, Korea.
FAU - Kim, Sang Soo
AU  - Kim SS
AD  - Department of Internal Medicine and Biomedical Research Institute, Pusan National 
      University Hospital, Busan, Korea.
FAU - Jin, Heung Yong
AU  - Jin HY
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical 
      Research Institute of Jeonbuk National University Hospital, Jeonbuk National 
      University Medical School, Jeonju, Korea.
FAU - Kim, Jeong Mi
AU  - Kim JM
AD  - Department of Internal Medicine and Biomedical Research Institute, Pusan National 
      University Hospital, Busan, Korea.
FAU - Jang, Min Hee
AU  - Jang MH
AD  - Department of Internal Medicine and Biomedical Research Institute, Pusan National 
      University Hospital, Busan, Korea.
FAU - Lee, Kyung Ae
AU  - Lee KA
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical 
      Research Institute of Jeonbuk National University Hospital, Jeonbuk National 
      University Medical School, Jeonju, Korea.
FAU - Lee, Ju Hyung
AU  - Lee JH
AD  - Department of Preventive Medicine, Jeonbuk National University Medical School, 
      Jeonju, Korea.
FAU - Chung, Seung Min
AU  - Chung SM
AD  - Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, 
      Korea.
FAU - Lyu, Young Sang
AU  - Lyu YS
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun 
      University Hospital, Chosun University College of Medicine, Gwangju, Korea.
FAU - Kim, Jin Hwa
AU  - Kim JH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun 
      University Hospital, Chosun University College of Medicine, Gwangju, Korea.
FAU - Kim, Sang Yong
AU  - Kim SY
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun 
      University Hospital, Chosun University College of Medicine, Gwangju, Korea.
FAU - Jang, Jung Eun
AU  - Jang JE
AD  - Department of Internal Medicine, Inje University College of Medicine, Busan, 
      Korea.
FAU - Kim, Tae Nyun
AU  - Kim TN
AD  - Department of Internal Medicine, Inje University College of Medicine, Busan, 
      Korea.
FAU - Kim, Sung Woo
AU  - Kim SW
AD  - Department of Internal Medicine, Daegu Catholic University School of Medicine, 
      Daegu, Korea.
FAU - Jeon, Eonju
AU  - Jeon E
AD  - Department of Internal Medicine, Daegu Catholic University School of Medicine, 
      Daegu, Korea.
FAU - Cho, Nan Hee
AU  - Cho NH
AD  - Department of Internal Medicine, Keimyung University Dongsan Medical Center, 
      Keimyung University School of Medicine, Daegu, Korea.
FAU - Kim, Mi-Kyung
AU  - Kim MK
AD  - Department of Internal Medicine, Keimyung University Dongsan Medical Center, 
      Keimyung University School of Medicine, Daegu, Korea.
FAU - Kim, Hye Soon
AU  - Kim HS
AD  - Department of Internal Medicine, Keimyung University Dongsan Medical Center, 
      Keimyung University School of Medicine, Daegu, Korea.
FAU - Nam-Goong, Il Seong
AU  - Nam-Goong IS
AD  - Department of Internal Medicine, Ulsan University Hospital, University of Ulsan 
      College of Medicine, Ulsan, Korea.
FAU - Kim, Eun Sook
AU  - Kim ES
AD  - Department of Internal Medicine, Ulsan University Hospital, University of Ulsan 
      College of Medicine, Ulsan, Korea.
FAU - Chung, Jin Ook
AU  - Chung JO
AD  - Department of Internal Medicine, Chonnam National University Medical School, 
      Gwangju, Korea.
FAU - Cho, Dong-Hyeok
AU  - Cho DH
AD  - Department of Internal Medicine, Chonnam National University Medical School, 
      Gwangju, Korea.
FAU - Lee, Chang Won
AU  - Lee CW
AD  - Department of Internal Medicine, Busan St. Mary's Hospital, Busan, Korea.
FAU - Kim, Young Il
AU  - Kim YI
AD  - Department of Internal Medicine, Daegu Catholic University School of Medicine, 
      Daegu, Korea.
FAU - Chung, Dong Jin
AU  - Chung DJ
AD  - Department of Internal Medicine, Chonnam National University Medical School, 
      Gwangju, Korea.
FAU - Won, Kyu Chang
AU  - Won KC
AD  - Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, 
      Korea.
FAU - Kim, In Joo
AU  - Kim IJ
AD  - Department of Internal Medicine and Biomedical Research Institute, Pusan National 
      University Hospital, Busan, Korea.
FAU - Park, Tae Sun
AU  - Park TS
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical 
      Research Institute of Jeonbuk National University Hospital, Jeonbuk National 
      University Medical School, Jeonju, Korea.
FAU - Kim, Duk Kyu
AU  - Kim DK
AD  - Department of Internal Medicine, Dong-A University Medical Center, Dong-A 
      University College of Medicine, Busan, Korea.
FAU - Shon, Hosang
AU  - Shon H
AD  - Department of Internal Medicine, Daegu Catholic University School of Medicine, 
      Daegu, Korea.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200812
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
CIN - Diabetes Metab J. 2022 Jan;46(1):162-163. PMID: 35135079
CIN - Diabetes Metab J. 2022 Jan;46(1):160-161. PMID: 35135080
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Retrospective Studies
PMC - PMC8497923
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Drug therapy, combination
OT  - Hypoglycemic agents
OT  - Injections
OT  - Insulin
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2020/08/15 06:00
MHDA- 2021/11/09 06:00
PMCR- 2021/09/01
CRDT- 2020/08/15 06:00
PHST- 2020/04/27 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/08/15 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
PHST- 2020/08/15 06:00 [entrez]
PHST- 2021/09/01 00:00 [pmc-release]
AID - 44.e46 [pii]
AID - dmj-2020-0107 [pii]
AID - 10.4093/dmj.2020.0107 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2021 Sep;45(5):675-683. doi: 10.4093/dmj.2020.0107. Epub 2020 
      Aug 12.